Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Oncodesign and OSEO Announce Funding of EUR 13.4 Million

Published: Tuesday, March 12, 2013
Last Updated: Tuesday, March 12, 2013
Bookmark and Share
This private-public partnership project, which aims to put in place the first national subsidiary dedicated to personalized medicine in oncology, has a EUR 41 million overall investment budget.

In the presence of French president, Francois Hollande, Francois Drouin, OSEO's CEO and vice-president of the BPI (Banque Publique d'Investissement), announced to Philippe Genne, Oncodesign's CEO and leader of the IMODI (Innovative MODels Initiative), that this project will receive EUR 13.4 million in funding under the French Government's Investing for the Future program.

The IMODI research project is designed to make the selection of new effective treatments to combat eight cancer pathologies easier.

The aim of this national initiative is to pool the resources allocated to the development, profiling and evaluation of more than 200 predictive experimental cancer models and a wide range of derivative biological products and tests for molecular selection.

The project also plans to create a centralized biobank with more than 40,000 biological samples and powerful data analysis tools designed to identify tumor and immunological biomarkers, as well as those coming from the microbiome.

Under the management and coordination of Oncodesign, the seven-year project brings together six industrial groups (Sanofi, Servier, Ipsen, Pierre Fabre, Transgene and Biofortis), four SMEs (Oncomedics, Ariana Pharma, CTI BIOTECH and Oncodesign) and seven French institutions (Inserm [the French National Institute of Health and Medical Research], CNRS, [the French National Center for Scientific Research], the Georges Francois Leclerc Center in Dijon, the Leon Berard Center in Lyon for cancer research and treatment, Synergie Lyon Cancer, the University of Strasbourg and Toulouse University Hospital).

Each organization belongs to one of five competitiveness clusters with authority to certify projects: Medicen, for the Paris Region, Alsace Biovalley, Lyonbiopole, Atlanpole Biotherapies in Nantes and Cancer-Bio-Sante in Toulouse.

IMODI won the investment for the 'Focal-Point Research and Development Projects for Competitiveness Clusters'. It will benefit from EUR 13.4 million of public funding after the final signing with OSEO.

These subsidies and reimbursable advances will be allocated between the project's French institutions and financed partner SMEs.

IMODI's forecasted overall investment budget of EUR 41 million also includes private investment. Over the next ten years the project will create 350 jobs within the partner companies.

With EUR 300 million in funding available to OSEO, the call for 'Focal-Point Projects for Competitiveness Clusters in Research and Development' aims to support ambitious research and development partnership projects focusing on a particular industry or area of technology which offers significant potential for economic spin-offs.

"This project offers a unique opportunity to increase the rate of innovation and identification of cancer therapies and biomarkers, with the creation of an organized national structure designed for the development of personalized medicine which directly benefits patients," says Philippe Genne, Oncodesign's president and CEO.

"OSEO is proud to have provided support to the IMODI project on behalf of the French state, as part of the Investing for the Future program," adds Francois Drouin, CEO at OSEO and vice-president at the French Public Investment Bank.

Drouin continued, "The industry's requirements, the way that the partner organizations complement each other as well as their experience and collective interest, demonstrate the synergy which will ensure the sustainability of the sector and the creation of economic and scientific value in France."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oncodesign Enters into a Services Agreement with Eisai
The program aims to identify useful patient stratification biomarkers for Eisai’s Halaven® eribulin using patient-derived xenograft models.
Friday, December 26, 2014
Oncodesign and UCB Enter into a Research Collaboration
The partnership is based on Oncodesign's Nanocyclix® technology platform for next generation kinase inhibitors and UCB’s expertise in neurology.
Thursday, November 14, 2013
Oncodesign and Banook Central Imaging Sign a Collaboration Agreement
The global reaching partnership aims to provide clinical researchers with new biomarkers and validated image analysis protocols, ensuring a continuum from preclinical to clinical phase in the development of anticancer therapies.
Tuesday, September 10, 2013
Oncodesign Signs a Partnership Agreement with Sanofi
Oncodesign will apply its Nanocyclix® technology to one of Sanofi's kinase targets.
Tuesday, April 09, 2013
Oncodesign Signs Partnership Agreement with Sanofi
Oncodesign will apply its Nanocyclix(R) technology to one of Sanofi's kinase targets.
Thursday, March 28, 2013
Oncodesign and the LNGT Enter into a Research Collaboration
Collaboration to advance Oncodesign's Parkinson’s disease program towards clinical development.
Wednesday, December 19, 2012
Oncodesign Enters into a Research Collaboration and License Agreement with Sanofi
Collaboration for the application of Oncodesign’s Nanocyclix® technology to Sanofi’s kinase targets.
Saturday, September 15, 2012
Oncodesign and Ipsen Enter into a Research Collaboration
Partnership is based on Oncodesign's Nanocyclix(R) Technology for next generation kinase inhibitors and Ipsen’s expertise in Movement Disorders.
Thursday, January 05, 2012
Oncodesign and Ipsen Enter Into a Research Collaboration
Partnership is based on Oncodesign's Nanocyclix® technology for next generation kinase inhibitors and Ipsen’s expertise in movement disorders.
Thursday, January 05, 2012
Scientific News
Ketamine Metabolism Lifts Depression
NIH-funded team finds rapid-acting, non-addicting agent in mouse study.
Faster, Cheaper Way to Produce New Antibiotics
A novel way of synthesising a promising new antibiotic has been identified by scientists at the University of Bristol.
Process Contaminants in Vegetable Oils and Foods
Glycerol-based process contaminants found in palm oil, but also in other vegetable oils, margarines and some processed foods, raise potential health concerns for average consumers of these foods in all young age groups, and for high consumers in all age groups.
Improving Natural Killer Cancer Therapy
Vanderbilt University researchers discover transcription factor critical for NK cell expansion. Findings could lead to increased therapeutic efficacy.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
Autism, Cancer Share a Remarkable Number of Risk Genes
Researchers with the UC Davis Comprehensive Cancer Center, MIND Institute identify more than 40 common genes.
Number Of Known Genetic Risk Factors For Endometrial Cancer Doubled
An international collaboration of researchers has identified five new gene regions that increase a woman’s risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
Genetic Variant May Help Explain Why Labradors Are Prone To Obesity
A genetic variation associated with obesity and appetite in Labrador retrievers – the UK and US’s favourite dog breed – has been identified by scientists at the University of Cambridge. The finding may explain why Labrador retrievers are more likely to become obese than dogs of other breeds.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!